Persson MSM, Harman KE, Vinogradova Y, Langan SM, Hippisley-Cox J, Thomas KS, et al. Incidence, prevalence and mortality of bullous pemphigoid in England 1998-2017: a population-based cohort study. Br J Dermatol. 2021;184:68–77. https://doi.org/10.1111/bjd.19022

Article  CAS  PubMed  Google Scholar 

Williams HC, Wojnarowska F, Kirtschig G, Mason J, Godec TR, Schmidt E, et al. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet. 2017;389:1630–8. https://doi.org/10.1016/s0140-6736(17)30560-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee S, Rastogi S, Hsu DY, Nardone B, Silverberg JI. Association of bullous pemphigoid and comorbid health conditions: a case-control study. Arch Dermatol Res. 2021;313:327–32. https://doi.org/10.1007/s00403-020-02100-2

Article  CAS  PubMed  Google Scholar 

Chanprapaph K, Pratumchart N, Limtong P, Rutnin S, Sukasem C, Kungvalpivat P, et al. Dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid: a comparative study of 100 patients with bullous pemphigoid and diabetes mellitus. J Dermatol. 2021;48:486–96. https://doi.org/10.1111/1346-8138.15778

Article  CAS  PubMed  Google Scholar 

He MJ, Wang YJ, Ran DL, Fu DS, He Q, Zhang HY, et al. Relationship between bullous pemphigoid and malignancy: a Mendelian randomization study. J Dermatol. 2024;51:403–8. https://doi.org/10.1111/1346-8138.17100

Article  PubMed  PubMed Central  Google Scholar 

Kim BR, Lee KH, Paik K, Kim M, Bae JM, Choi CW, et al. Comorbid diseases in bullous pemphigoid: a population-based case-control study. J Dermatol. 2024;52:460–71. https://doi.org/10.1111/1346-8138.17577

Article  CAS  PubMed  Google Scholar 

Moiz A, Zolotarova T, Eisenberg MJ. Outpatient management of essential hypertension: a review based on the latest clinical guidelines. Ann Med. 2024;56:2338242 https://doi.org/10.1080/07853890.2024.2338242

Article  PubMed  PubMed Central  Google Scholar 

Danaei G, Ding EL, Mozaffarian D, Taylor B, Rehm J, Murray CJ, et al. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med. 2009;6:e1000058 https://doi.org/10.1371/journal.pmed.1000058

Article  PubMed  PubMed Central  Google Scholar 

Kalińska-Bienias A, Kowalczyk E, Jagielski P, Bienias P, Kowalewski C, Woźniak K. The association between neurological diseases, malignancies and cardiovascular comorbidities among patients with bullous pemphigoid: case-control study in a specialized polish center. Adv Clin Exp Med. 2019;28:637–42. https://doi.org/10.17219/acem/90922

Article  PubMed  Google Scholar 

Sim B, Fook-Chong S, Phoon YW, Koh HY, Thirumoorthy T, Pang SM, et al. Multimorbidity in bullous pemphigoid: a case-control analysis of bullous pemphigoid patients with age- and gender-matched controls. J Eur Acad Dermatol Venereol. 2017;31:1709–14. https://doi.org/10.1111/jdv.14312

Article  CAS  PubMed  Google Scholar 

Teixeira VB, Cabral R, Brites MM, Vieira R, Figueiredo A. Bullous pemphigoid and comorbidities: a case-control study in portuguese patients. An Bras Dermatol. 2014;89:274–8. https://doi.org/10.1590/abd1806-4841.20142516

Article  PubMed  PubMed Central  Google Scholar 

Yang YW, Chen YH, Xirasagar S, Lin HC. Increased risk of stroke in patients with bullous pemphigoid: a population-based follow-up study. Stroke. 2011;42:319–23. https://doi.org/10.1161/strokeaha.110.596361

Article  PubMed  Google Scholar 

Pankakoski A, Sintonen H, Ranki A, Kluger N. Comorbidities of bullous pemphigoid in a finnish cohort. Eur J Dermatol. 2018;28:157–61. https://doi.org/10.1684/ejd.2018.3243

Article  CAS  PubMed  Google Scholar 

Ganji R, Mahboubi-Fooladi Z, Shahidi-Dadras M, Tehranchinia Z, Abdollahimajd F, Ghalamkarpour F, et al. Brain MRI findings in patients with bullous pemphigoid: a case-control study. Exp Dermatol. 2023;32:542–6. https://doi.org/10.1111/exd.14748

Article  PubMed  Google Scholar 

Kibsgaard L, Rasmussen M, Lamberg A, Deleuran M, Olesen AB, Vestergaard C. Increased frequency of multiple sclerosis among patients with bullous pemphigoid: a population-based cohort study on comorbidities anchored around the diagnosis of bullous pemphigoid. Br J Dermatol. 2017;176:1486–91. https://doi.org/10.1111/bjd.15405

Article  CAS  PubMed  Google Scholar 

Kwa MC, Silverberg JI. Association between inflammatory skin disease and cardiovascular and cerebrovascular co-morbidities in US adults: analysis of nationwide inpatient sample data. Am J Clin Dermatol. 2017;18:813–23. https://doi.org/10.1007/s40257-017-0293-x

Article  PubMed  Google Scholar 

AşIran Serdar Z, Aktaş Karabay E, Yaşar S, Kazaz N. Clinical features, associated systemic diseases, mortality rates, and treatment protocols in a group of Turkish patients with bullous pemphigoid. Turk Klin Dermatol Özel. 2018;28:44–50. https://doi.org/10.5336/dermato.2018-61536

Article  Google Scholar 

Kalinska-Bienias A, Piotrowski T, Kowalczyk E, Lesniewska A, Kaminska M, Jagielski P, et al. Actigraphy-measured nocturnal wrist movements and assessment of sleep quality in patients with bullous pemphigoid: a pilot case–control study. Clin Exp Dermatol. 2019;44:759–65. https://doi.org/10.1111/ced.13902

Article  CAS  PubMed  Google Scholar 

Kılıç Sayar S, Sun GP, Küçükoğlu R. Comorbidities of bullous pemphigoid: a single-center retrospective case–control study from Turkey. Dermatol Ther. 2021;34:e15031 https://doi.org/10.1111/dth.15031

Article  CAS  PubMed  Google Scholar 

Wu CY, Wu CY, Li CP, Chou YJ, Lin YH, Chang YT. Association between dipeptidyl peptidase-4 inhibitors and risk of bullous pemphigoid in patients with type 2 diabetes: a population-based cohort study. Diabetes Res Clin Pract. 2021;171:108546 https://doi.org/10.1016/j.diabres.2020.108546

Article  CAS  PubMed  Google Scholar 

Martin E, Mauer I, Malzahn U, Heuschmann PU, Goebeler M, Benoit S. Comorbid diseases among bullous pemphigoid patients in Germany: new insights from a case-control study. J Dtsch Dermatol Ges. 2022;20:798–805. https://doi.org/10.1111/ddg.14738

Article  PubMed  Google Scholar 

Shen WC, Chiang HY, Chen PS, Lin YT, Kuo CC, Wu PY. Risk of all-cause mortality, cardiovascular disease mortality, and cancer mortality in patients with bullous pemphigoid. JAMA Dermatol. 2022;158:167–75. https://doi.org/10.1001/jamadermatol.2021.5125

Article  PubMed  Google Scholar 

Titou H, Kerrouch H, Frikh R, Hjira N. The association between bullous pemphigoid and comorbidities: a case-control study in Moroccan patients. Acta Dermatovenerol Alp Pannonica Adriat. 2022;31:7–11.

PubMed  Google Scholar 

Zhang B, Chen X, Liu Y, Chen F, Yang N, Li L. Relationship between bullous pemphigoid and metabolic syndrome: a 12-year case-control study conducted in China. Ther Adv Chronic Dis. 2022;13:20406223221130707 https://doi.org/10.1177/20406223221130707

Article  PubMed  PubMed Central  Google Scholar 

Stirnadel-Farrant HA, Xu X, Kwiatek J, Jain P, Meyers J, Candrilli S, et al. Characteristics, treatment patterns, health care resource utilization and costs in patients with bullous pemphigoid: a retrospective analysis of US health insurance claims data. JAAD Int. 2023;13:117–25. https://doi.org/10.1016/j.jdin.2023.04.014

Article  PubMed  PubMed Central  Google Scholar 

Sumitra S, Chandran R, George AE. Proportion of Co-morbidities in patients with and without bullous pemphigoid: a cross-sectional study. J Clin Diagn Res. 2023;17:WC5–WC8. https://doi.org/10.7860/jcdr/2023/64111.18091

Article  CAS  Google Scholar 

Wu PC, Wu CY, Lyu YS, Chang YT, Wu CY. Association between bullous pemphigoid and atopic dermatitis: a population-based case-control study in Taiwan. Arch Dermatol Res. 2023;315:419–27. https://doi.org/10.1007/s00403-022-02372-w

Article  PubMed  Google Scholar 

Bastuji-Garin S, Joly P, Lemordant P, Sparsa A, Bedane C, Delaporte E, et al. Risk factors for bullous pemphigoid in the elderly: a prospective case–control study. J Invest Dermatol. 2011;131:637–43. https://doi.org/10.1038/jid.2010.301

Article  CAS  PubMed  Google Scholar 

Schmidt E, Sticherling M, Sárdy M, Eming R, Goebeler M, Hertl M, et al. S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid: 2019 update.